1 / 11

Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI

Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA. Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI. First impression . Wow !? I had predicted dramatic benefit with multiple 0’s in the P value. Older B-blocker trials (up to 1986). >27,000 patients from 28 trials

damisi
Télécharger la présentation

Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA Perspective onCOMMIT/CCS-2 Trial of Metoprolol in STEMI

  2. First impression • Wow !? • I had predicted dramatic benefit with multiple 0’s in the P value

  3. Older B-blocker trials (up to 1986) • >27,000 patients from 28 trials • Meta-analysis: • B-blocker (3.7%) • Control (4.3%) • 16% relative risk reduction • 95% CI: 1-30% • P=0.02 • On re-looking: • Lower risk patients studied • Wide confidence intervals on mortality benefit

  4. Evolution of use of B-Blockers in AMI • Benefits seen in meta-analysis of RCTs: reduced mortality, re-MI, VF, rec. ischemia • Initially contraindicated if CHF • Then, trials in outpatients with LV dysfunction, (with slow up-titration of dose over 3-6 mos)B-blockers shown to reduce mortality • The overlap: in AMI, CHF no longer seen as a contraindication to use of B blockers

  5. Looking at the data in COMMIT/CCS-2 • Benefit • Reduction in re-MI • Reduction in VF • Risk • Increased development of cardiogenic shock • Biologically plausible – a negative inotropic agent • Increased risk of shock in first 24-48 hours • Subgroup analysis: Shock developed in Patients with Killip III, tachycardia, or hypotension

  6. Current ACC/AHA guideline on the use of early -blocker in acute MI(ACC/AHA Task Force Report. J Am Coll Cardiol 2004;44:671-719 • Class I: Oral -blocker therapy should be administered promptly to those patients without a contraindication, irrespective of concomitant fibrinolytic therapy or performance of primary PCI. (Level of evidence: A) • Class IIa: It is reasonable to administer iv -blocker promptly to STEMI patients without contraindications, especially if a tachyarrhythmia or hypertension is present. (Level of evidence: B)

  7. Current ESC Guideline for the use of early -blocker in acute MI(ESC Task Force Report. Euro Heart J 2003;24:28-66 ……the use of iv -blockade in the acute phase of infarction in many countries is extremely low. There is a good case for the greater use of an iv -blocker when there is tachycardia (in the absence of heart failure), relative hypertension, or pain unresponsive to opioids. It may be prudent to test the patient’s response to this form of therapy by first using a short-acting preparation. In most patients, however, oral -blockade will suffice.

  8. Conclusions: B-Blockade in Acute MI • One size does not fit all • Avoid IV B-blocker for patients with evidence of compromised LV Function • Start oral B blocker after 1-2 days, when stable with lower doses, and titrate upward • Low-medium risk patients benefit from early IV -> oral beta-blockade • For all medications: Need to balance benefit and risk, for each patient

  9. Lessons Learned from 2x2 Clinical Trials • In 2x2 trial, if one is + and the other -, it provides a ‘negative control’ that reinforces the positive intervention • ISIS-4/ AMI ACE inhibitor +benefitGISSI-3 Nitrates no benefit • HOPE Vasc. ACE inhibitor +benefitGISSI-Prev. Dis Vit E no benefit • PROVE IT- ACS High-dose statin +benefit TIMI 22 Antibiotic no benefit • COMMIT/ AMI Clopidogrel +benefit CCS-2 Metoprotol +/-benefit

  10. COMMIT/CCS-2: Major contribution • 10 million AMI/year worldwide, ~3 million STEMI • For metoprolol, • We learn appropriate use for ‘well-established’ class • New data will avoid excess risk, but allow benefit in appropriate patients • For clopidogrel, • New addition for treatment for STEMI • Improved patency, mortality and morbidity • Could prevent 20,000 – 30,000 deaths, MI’s or strokes per year worldwide

More Related